Life Technologies and DaAn Gene announce amalgamation
Life Technologies Corporation has announced that they have signed an agreement with DaAn Gene, China?s premier bio-tech enterprise, to form Life Technologies DaAn Diagnostics.
Life Technologies Corporation has announced that they have signed an agreement with DaAn Gene, China’s premier bio-tech enterprise, to form Life Technologies DaAn Diagnostics.
Based in Guangzhou, Life Technologies DaAn Diagnostics will develop and produce a portfolio of molecular diagnostic assays. It is expected that the move will play a key role in disease prevention. The venture allows both companies to expand the use of capillary electrophoresis technology into the Chinese clinical diagnostics market.
Gregory Lucier, chairman and CEO of Life Technologies, said, “This joint venture strengthens the foundation of our clinical diagnostics business and represents a big leap forward for our business in China. The products will play a key role in disease prevention and therapy selection.”
Zhou Xinyu, CEO of DaAn Gene, commented, “Today, the cooperation with Life Technologies introduces DaAn’s products to the global marketplace, while bringing Life’s superior technologies into China’s IVD market. Together, we are working towards becoming a premium IVD product supplier that has global impact.”
For more information please visit ref="http://www.lifetechnologies.com">www.lifetechnologies.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
